On September 2, 2021 Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Secarna Pharmaceuticals GmbH & Co. KG ("Secarna"), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide ("ASO") therapies to address challenging or previously undruggable targets via its LNAplus platform, reported that they have expanded their strategic partnership in the field of ASO-based therapeutics (Press release, Evotec, SEP 2, 2021, View Source;announcements/press-releases/p/evotec-and-secarna-pharmaceuticals-expand-strategic-partnership-in-the-field-of-antisense-drug-discovery-6094 [SID1234587222]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The new agreement expands the ongoing successful collaboration between Evotec and Secarna initiated in August 2020. The parties are now also working on industry partners’ discovery, research and development programmes, leveraging Secarna’s industry-leading antisense oligonucleotide expertise with Evotec’s unparalleled discovery and development capabilities.
Dr Craig Johnstone, Chief Operating Officer of Evotec, said: "We are delighted to open our strategic partnership with Secarna for third-party programmes. Secarna’s validated ASO technology provides a highly promising pathway to access targets commonly deemed ‘undruggable’. Leveraging Secarna’s LNAplus technology through the capacity and capabilities of Evotec’s multimodality drug discovery platform will unlock a vast opportunity space for a broad range of partnerships with third parties to develop disease-modifying therapies in indications with high unmet medical need."
Alexander Gebauer, MD, PhD, Chief Executive Officer of Secarna Pharmaceuticals, said: "We are excited to further expand our successful alliance with Evotec. Integrating our proven expertise in the field of antisense discovery into Evotec’s well established discovery and development platform, we form a strong foundation for enabling and strengthening third-party pipelines with our LNAplus ASOs. We are looking forward to continue working with Evotec to make new therapeutic options available to industry partners and the many patients who urgently need them."